Abstract
Background: A novel peptide known as Elabela was recently discovered; it
functions similarly to apelin and acts through apelin receptors. This research
is to compare the characteristics and biological roles of apelin and Elabela in
patients with metabolic syndrome who are obese and those who are not.
Patients and Methods: A cross-sectional study included 90 participants, ages
20–45, whose samples were collected from Al-Yarmouk-Hospital/Al-
Karkh/Baghdad, from April–July/2024. Classified into three groups: group1
was obese metabolic syndrome patients (N=30), group 2 was metabolic
syndrome patients without obesity (N=30), and group 3 was control (N=30).
Anthropometrics and parameters were assessed for all study groups. Fasting
blood glucose levels and lipid profiles were determined using an enzymatic
process with spectrophotometric methods, while insulin, apelin, and Elabela
were evaluated by enzyme-linked immunosorbent assay.
Results: The result shows a significant difference in Body Mass Index, Waist
to Hip Ratio, Lipid profile, FBS, apelin, insulin, and HOMA-IR, while there
was no significant difference between the study groups in Elabela levels. In
addition, there is a positive correlation between apelin and BMI, FBS, and
insulin. apelin levels have a higher diagnostic value for obesity than metabolic
syndrome, respectively.
Conclusion: This study suggests that apelin and Elabela are powerful
modulators of the metabolism of adipose cell and highlights the crucial role of
apelin in MetS in both non-obese and obese MetS, as well as in clinical and
biochemical markers associated with obesity.
functions similarly to apelin and acts through apelin receptors. This research
is to compare the characteristics and biological roles of apelin and Elabela in
patients with metabolic syndrome who are obese and those who are not.
Patients and Methods: A cross-sectional study included 90 participants, ages
20–45, whose samples were collected from Al-Yarmouk-Hospital/Al-
Karkh/Baghdad, from April–July/2024. Classified into three groups: group1
was obese metabolic syndrome patients (N=30), group 2 was metabolic
syndrome patients without obesity (N=30), and group 3 was control (N=30).
Anthropometrics and parameters were assessed for all study groups. Fasting
blood glucose levels and lipid profiles were determined using an enzymatic
process with spectrophotometric methods, while insulin, apelin, and Elabela
were evaluated by enzyme-linked immunosorbent assay.
Results: The result shows a significant difference in Body Mass Index, Waist
to Hip Ratio, Lipid profile, FBS, apelin, insulin, and HOMA-IR, while there
was no significant difference between the study groups in Elabela levels. In
addition, there is a positive correlation between apelin and BMI, FBS, and
insulin. apelin levels have a higher diagnostic value for obesity than metabolic
syndrome, respectively.
Conclusion: This study suggests that apelin and Elabela are powerful
modulators of the metabolism of adipose cell and highlights the crucial role of
apelin in MetS in both non-obese and obese MetS, as well as in clinical and
biochemical markers associated with obesity.
Keywords
Apelin
APJ
Elabela
metabolic syndrome
Obesity